Unique ID issued by UMIN | UMIN000026409 |
---|---|
Receipt number | R000030342 |
Scientific Title | The research of factor influencing gefitinib-induced toxicity in patients with non-small cell lung cancer |
Date of disclosure of the study information | 2017/03/05 |
Last modified on | 2018/10/06 15:54:45 |
The research of factor influencing gefitinib-induced toxicity in patients with non-small cell lung cancer
The research of factor influencing gefitinib-induced toxicity in patients with non-small cell lung cancer
The research of factor influencing gefitinib-induced toxicity in patients with non-small cell lung cancer
The research of factor influencing gefitinib-induced toxicity in patients with non-small cell lung cancer
Japan |
Non-small cell lung cancer
Pneumology | Hematology and clinical oncology |
Malignancy
YES
To evaluate the relationship between pharmacokinetics of gefitinib and genetic polymorphisms of metabolic enzymes and transporters
Pharmacokinetics
To elucidate the pharmacokinetic factors relating gefitinib-induced toxicity
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Gefitinib
20 | years-old | <= |
Not applicable |
Male and Female
1) Histologically or cytologically confirmed non-small cell lung cancer
2) Positive for EGFR sensitive mutation
3) Unresectable advanced or recurrent disease
4) Age is over 20 years.
5) Performance status (ECOG) is 0 to 2
6) Adequate organ function, evidenced by following laboratory results within 14 days prior to starting chemotherapy
Absolute neutrophil count>1,500/mm3
Platelet count>100,000/mm3
Hemoglobin>8.0g/dL
AST and ALT<2.5 times the upper limit of normal(ULN)
Total bilirubin<2.0mg/dL
7) Signed, written informed concent is obtained
1) Interstitial pneumonia, pulmonary fibrosis
2) Severe active infection
3) Serological positive for HBs-antigen or HCV-antibody
4) Previous therapy with pazopanib
5) Unstable angina or myocardial infarction within 3 months
6) Severe complication (e.g., uncontrollable diabetis mellitus, liver disease)
7) Active synchronous cancer
8) Severe psychiatric disorder
9) Pregnant or lactating women, or men and women without wanting pregnancy
10) Severe hypersensitivity to medicine
11) Taking medicines affecting CYP3A4 within one week before starting gefitinib therapy (e.g., phenytoin, carbamazepine, rifampicin, phenobarbital, ketokonazole, macrolide)
12) Taking proton pump inhibitor or H2 blocker within one week before starting gefitinib therapy
13) Patients who were judged inappropriate for the study
30
1st name | |
Middle name | |
Last name | Hiroo Ishida |
Showa University School of Medicine
Division of Medical Oncology, Department of Medicine
1-5-8 Hatanodai, Shinagawa-ku, Tokyo
03-3784-8000
hishida@med.showa-u.ac.jp
1st name | |
Middle name | |
Last name | Hiroo Ishida |
Showa University School of Medicine
Division of Medical Oncology, Department of Medicine
1-5-8 Hatanodai, Shinagawa-ku, Tokyo
03-3784-8000
hishida@med.showa-u.ac.jp
Showa University School of Medicine
Showa University School of Medicine
Other
NO
2017 | Year | 03 | Month | 05 | Day |
Unpublished
Completed
2013 | Year | 11 | Month | 08 | Day |
2013 | Year | 12 | Month | 01 | Day |
2018 | Year | 09 | Month | 30 | Day |
2017 | Year | 03 | Month | 05 | Day |
2018 | Year | 10 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030342
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |